TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 60-66

  Zainuddin, Norafiza ^a   Berglund, Mattias ^a   Wanders, Alkwin ^a   Ren, Zhi Ping ^a   Amini, Rose Marie ^a   Lindell, Monica ^b   Kanduri, Meena ^a   Roos, Göran ^c   Rosenquist, Richard ^a   Enblad, Gunilla ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Diffuse large B cell lymphoma; Germinal center subtype; MDM2 SNP309; Survival; TP53 codon 72 polymorphism; TP53 mutation

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE DELETION; GERMINAL CENTER; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MUTATION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55049116604     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.06.022     Document Type: Article

References (55)

1. Anderson J.R., Armitage J.O., and Weisenburger D.D. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 9 7 (1998) 717-720
2. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 6769 (2000) 503-511
3. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 25 (2002) 1937-1947
4. Berglund M., Thunberg U., Amini R.M., Book M., Roos G., Erlanson M., et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 18 8 (2005) 1113-1120
5. Chang C.C., McClintock S., Cleveland R.P., Trzpuc T., Vesole D.H., Logan B., et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28 4 (2004) 464-470
6. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 1 (2004) 275-282
7. Kastan M.B., Canman C.E., and Leonard C.J. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 14 1 (1995) 3-15
8. Sigal A., and Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60 24 (2000) 6788-6793
9. Harris C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88 20 (1996) 1442-1455
10. Peller S., and Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 21 3 (2003) 277-284
11. Ichikawa A. Prognostic and predictive significance of p53 mutation in aggressive B-cell lymphoma. Int J Hematol 71 3 (2000) 211-220
12. Hollstein M., Hergenhahn M., Yang Q., Bartsch H., Wang Z.Q., and Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 431 2 (1999) 199-209
13. Moller M.B., Ino Y., Gerdes A.M., Skjodt K., Louis D.N., and Pedersen N.T. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 13 3 (1999) 453-459
14. Sander C.A., Yano T., Clark H.M., Harris C., Longo D.L., Jaffe E.S., et al. p53 mutation is associated with progression in follicular lymphomas. Blood 82 7 (1993) 1994-2004
15. Greiner T.C., Moynihan M.J., Chan W.C., Lytle D.M., Pedersen A., Anderson J.R., et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87 10 (1996) 4302-4310
16. Wilda M., Bruch J., Harder L., Rawer D., Reiter A., Borkhardt A., et al. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children. Leukemia 18 3 (2004) 584-588
17. Dohner H., Fischer K., Bentz M., Hansen K., Benner A., Cabot G., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85 6 (1995) 1580-1589
18. Ichikawa A., Kinoshita T., Watanabe T., Kato H., Nagai H., Tsushita K., et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337 8 (1997) 529-534
19. Leroy K., Haioun C., Lepage E., Le Metayer N., Berger F., Labouyrie E., et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 13 7 (2002) 1108-1115
20. Young K.H., Weisenburger D.D., Dave B., Smith L., Sanger W., Iqbal J., et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 110 13 (2007) 4396-4405
21. Barrans S.L., Carter I., Owen R.G., Davies F.E., Patmore R.D., Haynes A.P., et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99 4 (2002) 1136-1143
22. Osada M., Ishioka C., Ichinohasama R., Kadowaki I., Murakawa Y., Watanabe M., et al. Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma. Anticancer Drug Des 14 2 (1999) 107-114
23. Zhang Z., and Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 5 1 (2005) 9-20
24. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 5 (2004) 591-602
25. Bougeard G., Baert-Desurmont S., Tournier I., Vasseur S., Martin C., Brugieres L., et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43 6 (2006) 531-533
26. Lind H., Zienolddiny S., Ekstrom P.O., Skaug V., and Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119 3 (2006) 718-721
27. Menin C., Scaini M.C., De Salvo G.L., Biscuola M., Quaggio M., Esposito G., et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98 4 (2006) 285-288
28. Bond G.L., Hirshfield K.M., Kirchhoff T., Alexe G., Bond E.E., Robins H., et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66 10 (2006) 5104-5110
29. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108 2 (2004) 196-199
30. Galic V., Willner J., Wollan M., Garg R., Garcia R., Goff B.A., et al. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46 3 (2007) 239-247
31. Tommiska J., Eerola H., Heinonen M., Salonen L., Kaare M., Tallila J., et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11 14 (2005) 5098-5103
32. Toyama T., Zhang Z., Nishio M., Hamaguchi M., Kondo N., Iwase H., et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9 3 (2007) R34
33. Bonafe M., Ceccarelli C., Farabegoli F., Santini D., Taffurelli M., Barbi C., et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 9 13 (2003) 4860-4864
34. Saffari B., Bernstein L., Hong D.C., Sullivan-Halley J., Runnebaum I.B., Grill H.J., et al. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int J Gynecol Cancer 15 5 (2005) 952-963
35. Kochethu G., Delgado J., Pepper C., Starczynski J., Hooper L., Krishnan S., et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res 30 9 (2006) 1113-1118
36. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 5 (1994) 1361-1392
37. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987-94.
38. Amini R.M., Berglund M., Rosenquist R., Von Heideman A., Lagercrantz S., Thunberg U., et al. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma 43 11 (2002) 2179-2189
39. Kamata H., Mitani S., Fujiwara M., Aoki N., Okada S., and Mori S. Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin's lymphomas. Clin Exp Med 7 2 (2007) 39-46
40. Kerbauy F.R., Colleoni G.W., Saad S.T., Regis Silva M.R., Correa Alves A., Aguiar K.C., et al. Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature. Leuk Lymphoma 45 10 (2004) 2071-2078
41. Koduru P.R., Raju K., Vadmal V., Menezes G., Shah S., Susin M., et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 90 10 (1997) 4078-4091
42. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28 6 (2007) 622-629
43. Beroud C., and Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21 3 (2003) 176-181
44. Hamroun D., Kato S., Ishioka C., Claustres M., Beroud C., and Soussi T. The UMD TP53 database and website: update and revisions. Hum Mutat 27 1 (2006) 14-20
45. Bhatia K.G., Gutierrez M.I., Huppi K., Siwarski D., and Magrath I.T. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res 52 15 (1992) 4273-4276
46. Klumb C.E., Furtado D.R., de Resende L.M., Carrico M.K., Coelho A.M., de Meis E., et al. DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications. Eur J Haematol 71 2 (2003) 81-90
47. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 5015 (1991) 49-53
48. Boersma B.J., Howe T.M., Goodman J.E., Yfantis H.G., Lee D.H., Chanock S.J., et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98 13 (2006) 911-919
49. Hirata H., Hinoda Y., Kikuno N., Kawamoto K., Suehiro Y., Tanaka Y., et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 13 14 (2007) 4123-4129
50. Ohmiya N., Taguchi A., Mabuchi N., Itoh A., Hirooka Y., Niwa Y., et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24 27 (2006) 4434-4440
51. Sanchez-Carbayo M., Socci N.D., Kirchoff T., Erill N., Offit K., Bochner B.H., et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res 13 11 (2007) 3215-3220
52. Hartmann E., Fernandez V., Stoecklein H., Hernandez L., Campo E., and Rosenwald A. Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. Haematologica 92 4 (2007) 574-575
53. Alhopuro P., Ylisaukko-Oja S.K., Koskinen W.J., Bono P., Arola J., Jarvinen H.J., et al. The MDM2 promoter polymorphism SNP309T->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42 9 (2005) 694-698
54. Wang Y.C., Chen C.Y., Chen S.K., Chang Y.Y., and Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5 1 (1999) 129-134
55. Sturm I., Bosanquet A.G., Hummel M., Dorken B., and Daniel P.T. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 5 (2005) 105